# A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

> **NCT00782717** · PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 263 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
- **OTHER:** Nepafenac ophthalmic suspension vehicle
- **DRUG:** Prednisolone acetate ophthalmic suspension (OMNIPRED)

## Key facts

- **NCT ID:** NCT00782717
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782717, "A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00782717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*